The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant

• Published in: The Lancet infectious diseases Vol. 25; no. 3; pp. e122 - e123
• Main Authors: Suthar, Mehul S, Manning, Kelly E, Ellis, Madison L, Jain, Shilpi, Bechnak, Kareem, Vander Velden, Jake, Laboune, Farida, Henry, Amy R, Godbole, Sucheta, Kim, Sungjin, Sahoo, Malaya K, Paredes, Isabel, Dib, Serena M, Kalash, Suha, Radi, Christelle, Hicks, Heather, Tamin, Azaibi, Gardner, Meredith, Bowen, Nicole, Cook, Peter, Paden, Clinton, Harcourt, Jennifer, Pinsky, Benjamin A, Douek, Daniel C, Rouphael, Nadine, Moreno, Alberto
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.03.2025; Elsevier Limited
• Subjects: Antibodies; COVID-19; COVID-19 vaccines; FDA approval; Health sciences; Immune response; Immune response (cell-mediated); Immunization; Infectious diseases; Mutation; Severe acute respiratory syndrome coronavirus 2
• ISSN: 1473-3099; 1474-4457; 1474-4457
• DOI: 10.1016/S1473-3099(25)00007-6

The limitations of this study include the small cohort size, age group, examination of a single timepoint, and unknown effect of previous SARS-CoV-2 exposure or the cellular immune responses. The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. MSS served in an advisory role and received funds to conduct research from Ocugen.